Compare Stocks: VKTX, NVO, LLY, and HIMS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$30.83 -8.7%	$32.37	$13.74 ▼ $65.30	$7.25B	2.4	26.05 million shs	7.70 million shs
LLY Eli Lilly and Company	$1,248.35 -0.6%	$1,180.14	$694.23 ▼ $1,292.65	$1.18T	0.51	3.09 million shs	901,941 shs
NVO Novo Nordisk A/S	$46.91 +0.4%	$47.69	$35.12 ▼ $64.16	$209.34B	0.76	17.73 million shs	4.22 million shs
VKTX Viking Therapeutics	$32.98 -2.7%	$35.29	$22.96 ▼ $43.15	$3.86B	0.69	2.53 million shs	721,457 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	0.00%	+19.60%	+19.81%	+42.00%	-24.39%
LLY Eli Lilly and Company	0.00%	+6.35%	+5.11%	+17.88%	+76.90%
NVO Novo Nordisk A/S	0.00%	+1.96%	-4.00%	+4.23%	-17.72%
VKTX Viking Therapeutics	0.00%	+2.11%	-2.59%	+9.71%	+30.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HIMS Hims & Hers Health	$30.83 -8.7%	$32.37	$13.74 ▼ $65.30	$7.25B	2.4	26.05 million shs	7.70 million shs
LLY Eli Lilly and Company	$1,248.35 -0.6%	$1,180.14	$694.23 ▼ $1,292.65	$1.18T	0.51	3.09 million shs	901,941 shs
NVO Novo Nordisk A/S	$46.91 +0.4%	$47.69	$35.12 ▼ $64.16	$209.34B	0.76	17.73 million shs	4.22 million shs
VKTX Viking Therapeutics	$32.98 -2.7%	$35.29	$22.96 ▼ $43.15	$3.86B	0.69	2.53 million shs	721,457 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HIMS Hims & Hers Health	0.00%	+19.60%	+19.81%	+42.00%	-24.39%
LLY Eli Lilly and Company	0.00%	+6.35%	+5.11%	+17.88%	+76.90%
NVO Novo Nordisk A/S	0.00%	+1.96%	-4.00%	+4.23%	-17.72%
VKTX Viking Therapeutics	0.00%	+2.11%	-2.59%	+9.71%	+30.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HIMS Hims & Hers Health	2.19	Hold	$32.17	4.33% Upside
LLY Eli Lilly and Company	2.83	Moderate Buy	$1,292.18	3.51% Upside
NVO Novo Nordisk A/S	2.21	Hold	$64.94	38.42% Upside
VKTX Viking Therapeutics	2.75	Moderate Buy	$96.63	192.95% Upside

Current Analyst Ratings Breakdown

Latest VKTX, NVO, LLY, and HIMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	HIMS Hims & Hers Health	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $35.00
8/18/2026	VKTX Viking Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$47.00
8/12/2026	NVO Novo Nordisk A/S	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/11/2026	LLY Eli Lilly and Company	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	HIMS Hims & Hers Health	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$25.00 ➝ $26.00
8/11/2026	HIMS Hims & Hers Health	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$25.00 ➝ $30.00
8/11/2026	HIMS Hims & Hers Health	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$21.00 ➝ $28.00
8/11/2026	HIMS Hims & Hers Health	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$35.00 ➝ $33.00
8/11/2026	HIMS Hims & Hers Health	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$30.00 ➝ $32.00
8/11/2026	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $42.00

(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HIMS Hims & Hers Health	$2.58B	2.79	$0.76 per share	40.36	$2.38 per share	12.96
LLY Eli Lilly and Company	$65.18B	18.03	$25.00 per share	49.94	$28.07 per share	44.47
NVO Novo Nordisk A/S	$329.43B	0.64	$4.71 per share	9.97	$6.58 per share	7.13
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$5.65 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HIMS Hims & Hers Health	$128.37M	-$0.63	N/A	61.67	N/A	-5.51%	-6.51%	-1.20%	11/9/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	41.92	27.21	1.48	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
NVO Novo Nordisk A/S	$15.51B	$4.09	11.46	13.92	4.23	35.36%	61.20%	21.49%	11/4/2026 (Estimated)
VKTX Viking Therapeutics	-$359.64M	-$4.66	N/A	N/A	N/A	N/A	-94.56%	-82.75%	10/28/2026 (Estimated)

Latest VKTX, NVO, LLY, and HIMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	HIMS Hims & Hers Health	-$0.0498	-$0.37	-$0.3202	-$0.37	$698.90 million	$753.21 million
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/5/2026	Q2 2026	NVO Novo Nordisk A/S	$0.77	$0.96	+$0.19	$0.72	$10.89 billion	$11.98 billion
7/29/2026	Q2 2026	VKTX Viking Therapeutics	-$1.21	-$1.10	+$0.11	-$1.10	N/A	N/A
6/30/2026	Q2 2026	NVO Novo Nordisk A/S	N/A	$0.9440	N/A	$0.72	N/A	$11.98 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
LLY Eli Lilly and Company	$6.92	0.55%	+15.18%	23.22%	11 Years
NVO Novo Nordisk A/S	$0.81	1.73%	+21.74%	19.80%	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest VKTX, NVO, LLY, and HIMS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.59%	8/14/2026	8/14/2026	9/10/2026
8/5/2026	NVO Novo Nordisk A/S		$0.5786	2.58%	8/17/2026	8/17/2026	8/25/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HIMS Hims & Hers Health	4.21	0.93	0.87
LLY Eli Lilly and Company	1.41	1.35	1.00
NVO Novo Nordisk A/S	0.59	0.79	0.56
VKTX Viking Therapeutics	N/A	4.72	4.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HIMS Hims & Hers Health	63.52%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
HIMS Hims & Hers Health	11.76%
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%
VKTX Viking Therapeutics	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HIMS Hims & Hers Health	2,442	233.31 million	205.88 million	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
NVO Novo Nordisk A/S	69,505	4.47 billion	4.46 billion	Optionable
VKTX Viking Therapeutics	20	116.65 million	110.47 million	Optionable

VKTX, NVO, LLY, and HIMS Headlines

Recent News About These Companies

Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 32,564 Viking Therapeutics, Inc. $VKTX

August 22 at 5:11 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Upgraded to Hold at Zacks Research

August 20, 2026 | marketbeat.com

How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?

August 19, 2026 | finance.yahoo.com

Timothy G. Youngquist 2020 Irrevocable Trust Has $10.61 Million Position in Viking Therapeutics, Inc. $VKTX

August 19, 2026 | marketbeat.com

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

August 19, 2026 | finance.yahoo.com

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

August 17, 2026 | zacks.com

2 GLP-1 Stocks That Could Double Your Money by 2031

August 16, 2026 | fool.com

Cantor Fitzgerald Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)

August 16, 2026 | theglobeandmail.com

Cornerstone Capital Inc. Takes $3.33 Million Position in Viking Therapeutics, Inc. $VKTX

August 15, 2026 | marketbeat.com

LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?

August 14, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Lowers Viking Therapeutics (NASDAQ:VKTX) Price Target to $65.00

August 13, 2026 | americanbankingnews.com

Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?

August 12, 2026 | finance.yahoo.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price

August 11, 2026 | marketbeat.com

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

August 8, 2026 | fool.com

Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX

August 8, 2026 | marketbeat.com

Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP

August 8, 2026 | marketbeat.com

Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

August 6, 2026 | fool.com

First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX

August 6, 2026 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 6, 2026 | marketbeat.com

The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Obesity Dosing Ambitions And Fresh Financing – Learn Why

August 4, 2026 | finance.yahoo.com

Viking Therapeutics (VKTX) Draws Fresh VK2735 Attention, Is It Still Below Fair Value?

August 4, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VKTX, NVO, LLY, and HIMS Company Descriptions

Hims & Hers Health NYSE:HIMS

$30.83 -2.95 (-8.72%)

As of 01:22 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company NYSE:LLY

$1,248.35 -7.05 (-0.56%)

As of 01:22 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$46.91 +0.17 (+0.37%)

As of 01:22 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Viking Therapeutics NASDAQ:VKTX

$32.98 -0.91 (-2.68%)

As of 01:22 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VKTX, NVO, LLY, and HIMS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VKTX, NVO, LLY, and HIMS Earnings

Compare Dividends

Latest VKTX, NVO, LLY, and HIMS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VKTX, NVO, LLY, and HIMS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VKTX, NVO, LLY, and HIMS Company Descriptions

Hims & Hers Health NYSE:HIMS

Eli Lilly and Company NYSE:LLY

Novo Nordisk A/S NYSE:NVO

Viking Therapeutics NASDAQ:VKTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools